Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer

[1] Jemar A(2005)Cancer statistics, 2005 CA Cancer J Clin 55 10-30

[2] Murray T(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548-557

[3] Ward E(2009)Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer Cancer Chemother Pharmacol 65 159-166

[4] Shirasaka T(2007)A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27–9902 Step2) in patients with advanced gastric cancer using a continual reassessment method Jpn J Clin Oncol 37 924-929

[5] Shimamato Y(2009)Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial Jpn J Clin Oncol 39 713-719

[6] Ohshimo H(2007)Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial Ann Oncol 18 1673-1679

[7] Lee SJ(2008)Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction Ann Oncol 19 104-108

[8] Cho SH(2007)V-325 study group. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group J Clin Oncol 25 3210-3216

[9] Yoon JY(2005)Increased antitumor activity in combined treatment TS-1 and docetaxel Oncology 68 130-137

[10] Morita S(2006)Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer Oncology Rep 15 849-854

[1] Jemar A(2005)Cancer statistics, 2005 CA Cancer J Clin 55 10-30

[2] Murray T(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548-557

[3] Ward E(2009)Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer Cancer Chemother Pharmacol 65 159-166

[4] Shirasaka T(2007)A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27–9902 Step2) in patients with advanced gastric cancer using a continual reassessment method Jpn J Clin Oncol 37 924-929

[5] Shimamato Y(2009)Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial Jpn J Clin Oncol 39 713-719

[6] Ohshimo H(2007)Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial Ann Oncol 18 1673-1679

[7] Lee SJ(2008)Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction Ann Oncol 19 104-108

[8] Cho SH(2007)V-325 study group. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group J Clin Oncol 25 3210-3216

[9] Yoon JY(2005)Increased antitumor activity in combined treatment TS-1 and docetaxel Oncology 68 130-137

[10] Morita S(2006)Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer Oncology Rep 15 849-854